Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 40-kDa huntingtin-associated protein (HAP40, encoded by F8A1) is a conserved human protein entirely located within intron 22 of the factor VIII gene, but transcribed in the opposite direction[2][4]. The gene region containing F8A1 is duplicated in two other locations on the X chromosome (as F8A2 and F8A3)[4]. HAP40 acts as a RAB5A effector involved in early endosome trafficking, regulating the recruitment of huntingtin protein onto endosomes and modulating interactions with the cytoskeleton (increased actin interactions, reduced endosome motility)[2][3]. Its expression is abundant in many tissues, and its evolutionary conservation suggests a biologically important role, although its precise physiological or pathological functions are still under investigation[2][4]. Alterations in HAP40 protein levels are observed in Huntington’s Disease, suggesting a potential link between its function and neurodegenerative processes, but it is not a direct target for current therapeutic drugs[3]. The proximity of F8A1 to factor VIII is relevant in genetic studies, as recombination or inversion events involving F8A1/F8A2/F8A3 may disrupt factor VIII and cause hemophilia A (but F8A1 itself is not a coagulation factor nor involved in blood clotting)[6].\n\nSummary of Most Important Points:\n- HAP40 (F8A1) is a vesicular trafficking effector, not a receptor, enzyme, transporter, or direct therapeutic target[2][3][4].\n- It is closely associated biologically with the huntingtin protein, and changes in its levels are relevant in Huntington's Disease[3].\n- It is *not* involved in coagulation itself; rather, its genomic location in the factor VIII gene is key for understanding inversion events causing hemophilia[2][6].\n- No known drugs, biomarkers, safety concerns, or therapeutic targeting mechanisms involve HAP40 to date.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 40-kDa huntingtin-associated protein (HAP40).